✨ Free AI Report
Adverum Biotechnologies, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Adverum Biotechnologies, Inc.
Research Preview

Adverum Biotechnologies, Inc.: Business Overview, Financials & Competitive Analysis

Adverum Biotechnologies is a clinical-stage company developing gene therapy product candidates to treat ocular diseases, with its lead product Ixo-vec in Phase 2 clinical trials for wet age-related macular degeneratio...

Analyst-debate audio for Adverum Biotechnologies, Inc.

AskCyborg analysts argue the bull and bear cases for Adverum Biotechnologies, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Adverum Biotechnologies, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Solid

Cyborg Score thesis

Gene therapy platform for prevalent ocular diseases with promising efficacy data, but success hinges on Phase 3 ARTEMIS trial...

Read the full analyst-debate transcript →
Industry Biotechnology - Gene Therapy (Ophthalmology)
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 22, 2026
AI-Verified Research
30+ Page Report

Get the Latest Adverum Biotechnologies, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Adverum Biotechnologies, Inc. Overview

Pro stress-test →

Adverum Biotechnologies is a clinical-stage company developing gene therapy product candidates to treat ocular diseases, with its lead product Ixo-vec in Phase 2 clinical trials for wet age-related macular degeneration and diabetic macular edema. The company's Phase 2 LUNA trial showed an 88% reduction in treatment burden and 54% injection freedom for Ixo-vec.

Strategic Profile

Pro stress-test →

The company is advancing its pivotal ARTEMIS Phase 3 trial for wet AMD, with patient enrollment exceeding expectations and anticipated topline data readout in Q1 2027. Adverum has a Buy consensus rating from 4 analysts as of January 2026.

Competitive Landscape

Pro stress-test →

Competitors include 4D Molecular Therapeutics, Caribou Biosciences, IVERIC bio, Voyager Therapeutics, and Regenxbio. Adverum competes in the gene therapy space for ocular diseases, where single-administration AAV-based therapies represent an emerging therapeutic paradigm targeting large wet AMD patient populations currently treated with frequent anti-VEGF injections.

Industry Context

Adverum Biotechnologies, Inc. operates in Biotechnology - Gene Therapy (Ophthalmology).

Key facts

Founded: 2006 · Headquarters: Redwood City, US · Employees: 199 · Market cap: $96.25M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Adverum Biotechnologies, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Adverum Biotechnologies, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Gene Therapy for Retinal DiseasesClinical-stage gene therapy developer for ocular and CNS diseases→Gene Therapy for Ocular DiseasesOphthalmology-focused biopharmaceutical company→AAV Gene Therapy PlatformAAV-based gene therapy company with multiple ocular programs→Cell and Gene TherapyGene therapy developer using proprietary AAV vectors→

Compare Adverum Biotechnologies, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Adverum Biotechnologies, Inc. operates in Biotechnology - Gene Therapy (Ophthalmology). See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Gene Therapy (Ophthalmology) research →
NEW · MCP server

Ask your AI assistant about Adverum Biotechnologies, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Adverum Biotechnologies, Inc. and its top competitor on Cyborg Score”
“What did Adverum Biotechnologies, Inc. do this quarter?”
“Is Adverum Biotechnologies, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Adverum Biotechnologies, Inc. do?+
Adverum Biotechnologies is a clinical-stage company developing gene therapy product candidates to treat ocular diseases, with its lead product Ixo-vec in Phase 2 clinical trials for wet age-related macular degeneratio...
What is Adverum Biotechnologies, Inc.'s Cyborg Score?+
Adverum Biotechnologies, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Adverum Biotechnologies, Inc.'s main competitors?+
Named competitors include Gene Therapy for Retinal Diseases, Gene Therapy for Ocular Diseases, AAV Gene Therapy Platform, Cell and Gene Therapy. The full competitive landscape is in the AskCyborg report.
How can I get the full Adverum Biotechnologies, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Adverum Biotechnologies, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Adverum Biotechnologies, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9GELEX Group Joint Stock Company9TTM Technologies, Inc.9Insulet Corporation9Marathon Petroleum Corporation9Seagate Technology Holdings plc9Howmet Aerospace Inc.9Investor AB9Micron Technology, Inc.9Taiwan Semiconductor Manufacturing Company Limited9NVIDIA Corporation8NIO Inc.8Seanergy Maritime Holdings Corp.8Grupo Aeroméxico, S.A.B. de C.V.8Gulf Medical Projects Company8Interloop Limited8Kyverna Therapeutics, Inc.8Tatton Asset Management Plc8Invictus Investment Company PLC